PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript
PTC Therapeutics, Inc. ( PTCT ) UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM EST Company Participants Matthew Klein - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript
PTC Therapeutics, Inc. ( PTCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Judah Frommer - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Huidong Wang - Barclays Bank PLC, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Luke Herrmann - Robert W.
Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of a loss of $1.19 per share. This compares to a loss of $1.39 per share a year ago.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.
PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwei Fang - Corporate Participant Matthew B. Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jenny Leigh Gonzalez-Armenta - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Joon So Lee - Truist Securities, Inc., Research Division Judah C.
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
